Overview
- On July 24 a 37-year-old volunteer in Oxford received the first dose of ChAdOx1 BDBV as a phase 1 safety and immunogenicity trial began and researchers are recruiting up to about 50 healthy adults.
- The vaccine uses Oxford’s ChAdOx1 chimpanzee adenovirus vector, the same platform behind the Oxford–AstraZeneca COVID-19 shot, and the team says it moved the candidate from concept to clinic in roughly eight weeks.
- The trial is funded by the Coalition for Epidemic Preparedness Innovations and the Serum Institute of India has produced a stockpile of about 620,000 doses to support further studies or rapid use if testing and approvals permit.
- The work responds to a fast-growing Bundibugyo Ebola outbreak in the DRC and Uganda that has caused more than 1,000 deaths and for which there are no licensed vaccines or treatments matched to this strain.
- If the vaccine proves safe and elicits strong immune responses, further trials in Uganda and targeted deployment could fill a critical gap in Ebola preparedness, but field testing will face regulatory steps and operational challenges in conflict-hit areas.